CandidoEdgardoRivera-LinaresMD

Hematology • Jacksonville, FL

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology, Sickle Cell & Other Anemias

Assistant Professor, Internal Medicine, Mayo Medical School

Join to view full profile

Dr. Rivera-Linares is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rivera-Linares' full profile

Already have an account?

Office
4500 San Pablo Rd S
Jacksonville, FL 32224
Phone+1 904-953-2000

Fax+1 904-953-2315

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1989 - 1992
University of Puerto Rico School of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 2002 - 2026
MD State Medical License 1992 - 2011
PA State Medical License 1991 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin Start of enrollment: 2007 Mar 01
Completed
Phase 2
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders Start of enrollment: 2005 Sep 01
Completed
Early Phase 1
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma Start of enrollment: 2008 Aug 25
Active, not recruiting
Phase 1, Phase 2
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) Start of enrollment: 2011 Apr 22
Terminated
Phase 3
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Start of enrollment: 2010 Nov 01
Completed
Phase 2
Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms Start of enrollment: 2012 Jun 11
Completed
Phase 1
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Start of enrollment: 2013 Dec 06
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

31 citations
Diagnosis and Management of Genetic Iron Overload Disorders
William C. Palmer, Prakash Vishnu, William Sanchez, Bashar Aqel, Doug Riegert-Johnson
Journal of General Internal Medicine. 2018-09-17
24 citations
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Ayalew Tefferi, Stacie Hudgens, Ruben A. Mesa, Robert Peter Gale, Srdan Verstovsek
Clinical Therapeutics. 2014-04-01
76 citations
Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic.
Robert D. McBane, Victor D. Torres Roldan, Alexander S. Niven, Rajiv K. Pruthi, Pablo Moreno Franco
Mayo Clinic Proceedings. 2020-11-01

Professional Memberships

American Society of Hematology - ASH
Member
American College of Physicians - ACP
Fellow
International Society on Thrombosis and Haemostasis - ISTH
Member

Other Languages

Spanish